Abstract
Hepatitis B virus (HBV) reactivation in kidney transplant recipients is a serious and understudied complication which seems to occur in 3 to 6% of HBs antigen (HBsAg)-negative patients. No data exists regarding HBV reactivation in patients receiving belatacept, an alternative to calcineurin inhibitors in renal transplantation but with which viral infections seem more frequent.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
